

Table 1: Demographics information of pediatric patients with COVID-19

Demographics information		Number (%)
		Mean (SD)/ Range
Sex; Boy / Girl, n(%)		12/9(57.1/42.9)
Age (Month)	<1	0
	1 - 6	3(14.28)
	6 - 12	1(4.76)
	12-72	4(19.04)
	>72	13(61.9)
	Age base month; Mean (SD)	91.5(68.38)
Weight (g), Mean (SD)		26.68(18.08)
History of contact		
First visit, n(%)	General physician	10(47.6)
	Specialist	5(23.8)
	Hospital	6(28.6)
History of travel over last 2 weeks; Yes/No, n(%)		0/21(0/100)
History of contact with suspected person; Yes/No, n(%)		4/17(19.04/80.95)
History of contact with definite positive person; Yes/No, n(%)		3/18(14.3/85.7)
History of hospital visits or hospitalizations over last month; Yes/No, n(%)		5/16(23.8/76.2)
History of influenza vaccine; Yes/No, n(%)		4/17(19/81)
History of routine vaccination; n(%)		20(95.2)
Underlying disease; n(%)	None	13(61.9)
	Asthma	2(9.5)
	Malignancy	2(9.5)
	Other	4(19)
History of using corticosteroid over last month; Yes/No, n(%)		1/20(4.8/95.2)
Chemotherapy or immunosuppressive drugs over last 3 months; Yes/No, n(%)		2/19(9.5/90.5)
History of consumption antibiotic over past two weeks; Yes/No, n(%)		12/9(42.9/57.1)

Table 2: Clinical finding of pediatric patients with COVID-19

Clinical finding		Number (%)
Complains; n(%)	Fever	13(61.9)
	Fatigue	2(9.5)
	Dry cough	8(38.1)
	Wet cough	4(19)
	Anorexia	3(14.3)
	Sputum	0(0)
	Sore throat	2(9.5)
	Diarrhea	4(19)
	Nausea	4(19)
	Vomit	8(38.1)
	Headache	1(4.8)
	Stomachache	3(14.3)
	Uncomfortable feeling in the abdomen	1(4.8)
	Convulsions	2(9.5)
	Sleepiness or loss of consciousness	1(4.8)
Sing and symptoms; n(%)	Fever	11(52.4)
	Chills	1(4.8)
	Cough	7(33.3)
	Weakness and lethargy	5(23.8)
	Discomfort in breathing	5(23.8)
	Chest pain	1(4.8)
	Myalgia	1(4.8)
	Anorexia	0
	Nausea and vomiting	3(14.3)
	Abdominal pain	1(4.8)
	Diarrhea	2(9.5)
	Neck mass	1(4.8)
	Loss of consciousness	1(4.8)
Cyanosis; n(%)		0
Grunting; n(%)		1(4.8)
Nasal flaring; n(%)		1(4.8)
Retraction sub or intercostal; n(%)		4(19)
Mottling; n(%)		1(4.8)
Urinary status; n(%)	Normal	18(85.7)
	Oliguria	3(14.3)
Fine crackles; n(%)		3(14.3)
Coarse crackles; n(%)		1(4.8)
Wheezing; n(%)		1(4.8)
Noise reduction; n(%)		2(9.5)
Temperature in emergency, Mean (SD)		37.46(1.07)

No. heartbeats in emergency, Mean (SD)		106.76(25.9)
No. breaths in emergency (min), Mean (SD)		36.48(15.45)
Tachycardia; n(%)		4 (19%)
Tachypnea; n(%)		11 (52/3%)
Bradycardia		2 (9%)
Comorbidity	Shock	0
	Cardiac arrhythmia	0
	ARDS	3(14.3)
	Acute cardiac injury	0
	AKI	2(9.5)

Table 3: Laboratory finding of pediatric patients with COVID-19

	Variable	Mean (±SD) n(%)
Blood test	White blood cells ($\times 10^3$ /ml)	8460(6438)
	Decreased	6(30)
	Lymphocytes ($\times 10^3$ /ml)	28(19.63)
	Polymorphonuclear leukocytes ($\times 10^9$ /L)	64(19.31)
	Haemoglobin(g/L)	12.33(5.54)
	Platelet count ($\times 10^9$ / L)	152290(78030.48)
	Blood urea nitrogen (mg/dL)	24(4796)
	Creatinine (mg/dL)	0.97(0.99)
	Blood potassium level(mmol/L)	4.57(1.14)
	Blood sodium levels(mmol/L)	131.84(30.53)
	Blood calcium levels(mg/dL)	8.55(1.56)
	INR (international normalized ratio)	1.26(0.21)
	Prothrombin time(s)	14.55(1.46)
	Activated partial thromboplastin time (s)	37.5(9.16)
	Creatine phosphokinase(U/L)	190.67(162.58)
	Decreased	1(33)
	Normal	2(66)
	Lactic acid dehydrogenase (U/L)	698.71(336.18)
	Increased	3(42)
	Normal	4(57)
	Alanine aminotransferase (U/L)	28.08(21.1)
	Normal range < 45	11(92)
	>45	1(8.3)
	Aspartate Aminotransferase(IU/L)	46.33(24.21)
	Normal range < 45	8(67)
	>45	4(34)
		0.9(0.84)
	Bilirubin direct (mg/dl)	
	Normal range <0.2	0

	>0.2	2(100)
	Bilirubin total $\mu\text{mol/L}$	1.65(0.77)
	Normal range <1.2	0
	>1.2	2(100)
RT-PCR	Positive/Negative	17/1(81/4.8)
ABG; Mean (SD), n(%) Child/adult	PH (7.35-7.45)	7.32(0.11)
	Increased	9(53)
	Decreased	5(29.4)
	Normal	2(18)
	PaCo ₂ (32-48 mmHg)	38.91(8.57)
	Increased	3(17.6)
	Decreased	2(11.8)
	Normal	12(70.6)
	Pao ₂ (83-108 mmHg)	72.80(28.92)
	Increased	1(5.9)
	Decreased	8(47)
	Normal	8(47)
	HCo ₃ (20-28 mEq/L)	20.52(5.17)
	Increased	5(29.4)
	Decreased	1(5.9)
	Normal	11(64.7)
	Base excess	-2.31(12.01)

Table 4: Radiology finding of pediatric patients with COVID-19

Variable	n(%)
CXR	
Peripheral airspace opacities ; n(%)	5(23.81)
Ground glass opacity; n(%)	5(23.81)
Lung consolidation; n(%)	7(33.33)
Pleural effusion; n(%)	6(28.57)
Patchy infiltration; n(%)	4(19.05)
cavitation	4(19.05)
Perihilar lymphadenopathy; n(%)	3(14.28)
Lung CT scan	
Peripheral airspace opacities; n(%)	12(57.14)
Ground glass opacity; n(%)	14(66.66)
Lung consolidation; n(%)	4(19.05)
Pleural effusion; n(%)	10(47.62)
Pathchyinfiltration; n(%)	7(33.33)
While lung; n(%)	6(28.57)
Cavitation; n(%)	14(66.66)
Perihilar lymphadenopathy; n(%)	8(38.09)
Crazy paving pattern; n(%)	9(42.85)
Centrolobular nodule; n(%)	6(28.57)
Reverse halo sign; n(%)	3(14.28)
Halo sign; n(%)	9(42.85)

Table 5: Treatment strategies of pediatric patients with COVID-19

Treatment strategies		Number (%)
Treatment; n(%)	Oseltamivir	8(38.1)
	Ribavirin	1(4.8)
	Kaletra :Lopinavir / Ritonavir	6(28.6)
	Chloroquine	8(38.1)
Antibiotics; n(%)		20(95.2)
Type of antibiotic during treatment;; n(%)	Azithromycin	2(9.5)
	Ceftriaxone	5(23.8)
	Vancomycin+Ceftriaxone	3(14.33)
	Clindamycin+Ceftriaxone	1(4.8)
	Vancomycin+Ceftriaxone+Azithromycin	1(4.8)
Oxygen therapy; n(%)	Oxygen with mask	6(28.6)
	Oxygen with hood	2(9.5)
	Intubation	2(9.5)
	Oxygen with hood intubation	1(4.8)
Death		4(19.04)
Discharge		17(80.95)